biostudies-literatureJia GNHLBI NIH HHS647-654.e10https://www.ebi.ac.uk/biostudies/studies/S-EPMC3626285biostudies-literatureUnknown130(3)<h4>Background</h4>Eosinophilic airway inflammation is heterogeneous in asthmatic patients. We recently described a distinct subtype of asthma defined by the expression of genes inducible by T(H)2 cytokines in bronchial epithelium. This gene signature, which includes periostin, is present in approximately half of asthmatic patients and correlates with eosinophilic airway inflammation. However, identification of this subtype depends on invasive airway sampling, and hence noninvasive biomarkers of this phenotype are desirable.<h4>Objective</h4>We sought to identify systemic biomarkers of eosinophilic airway inflammation in asthmatic patients.<h4>Methods</h4>We measured fraction of exhaled nitric oxide (Feno), peripheral blood eosinophil, periostin, YKL-40, and IgE levels and compared these biomarkers with airway eosinophilia in asthmatic patients.<h4>Results</h4>We collected sputum, performed bronchoscopy, and matched peripheral blood samples from 67 asthmatic patients who remained symptomatic despite maximal inhaled corticosteroid treatment (mean FEV(1), 60% of predicted value; mean Asthma Control Questionnaire [ACQ] score, 2.7). Serum periostin levels are significantly increased in asthmatic patients with evidence of eosinophilic airway inflammation relative to those with minimal eosinophilic airway inflammation. A logistic regression model, including sex, age, body mass index, IgE levels, blood eosinophil numbers, Feno levels, and serum periostin levels, in 59 patients with severe asthma showed that, of these indices, the serum periostin level was the single best predictor of airway eosinophilia (P = .007).<h4>Conclusion</h4>Periostin is a systemic biomarker of airway eosinophilia in asthmatic patients and has potential utility in patient selection for emerging asthma therapeutics targeting T(H)2 inflammation.The Journal of allergy and clinical immunologyPeriostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.PMC3626285HL097591HL080414P50 HL056385R01 HL095372HL095372U10 HL109146R01 HL080414R01 HL097591R01 HL066564HL66564HL56385Solberg ODArron JRWu LCBradding PBronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study GroupJia GAudusseau SFahy JVWoodruff PGErickson RWHamid QShikotra ACarter RHarris JMChoy DFMosesova SfalsePeriostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.<h4>Background</h4>Eosinophilic airway inflammation is heterogeneous in asthmatic patients. We recently described a distinct subtype of asthma defined by the expression of genes inducible by T(H)2 cytokines in bronchial epithelium. This gene signature, which includes periostin, is present in approximately half of asthmatic patients and correlates with eosinophilic airway inflammation. However, identification of this subtype depends on invasive airway sampling, and hence noninvasive biomarkers of this phenotype are desirable.<h4>Objective</h4>We sought to identify systemic biomarkers of eosinophilic airway inflammation in asthmatic patients.<h4>Methods</h4>We measured fraction of exhaled nitric oxide (Feno), peripheral blood eosinophil, periostin, YKL-40, and IgE levels and compared these biomarkers with airway eosinophilia in asthmatic patients.<h4>Results</h4>We collected sputum, performed bronchoscopy, and matched peripheral blood samples from 67 asthmatic patients who remained symptomatic despite maximal inhaled corticosteroid treatment (mean FEV(1), 60% of predicted value; mean Asthma Control Questionnaire [ACQ] score, 2.7). Serum periostin levels are significantly increased in asthmatic patients with evidence of eosinophilic airway inflammation relative to those with minimal eosinophilic airway inflammation. A logistic regression model, including sex, age, body mass index, IgE levels, blood eosinophil numbers, Feno levels, and serum periostin levels, in 59 patients with severe asthma showed that, of these indices, the serum periostin level was the single best predictor of airway eosinophilia (P = .007).<h4>Conclusion</h4>Periostin is a systemic biomarker of airway eosinophilia in asthmatic patients and has potential utility in patient selection for emerging asthma therapeutics targeting T(H)2 inflammation.2012-01-01T00:00:00Z2012 Sep2021-02-20T18:11:42Z2019-03-26T23:05:23ZS-EPMC36262852285787910.1016/j.jaci.2012.06.025